Skip to main content
    R

    Rapid Micro Biosystems Inc (RPID)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.74
    -0.00 (-0.43%)

    Market Cap: $32.65M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Rapid Micro Biosystems Inc (RPID) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rapid Micro Biosystems (RPID) has a market cap of $32.65M and an enterprise value of $37.11M. It kept -145.55% of revenue as net income over the last 12 months. Its share count is up 8.28% from a year earlier.

    Total Valuation

    Enterprise value is 13.63% above the market cap, as debt exceeds cash.

    Market Cap$32.65M
    Enterprise Value$37.11M
    Latest price (Nov 17, 2026)$0.74

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 6.41% in the quarter ended Jun 30, 2026 and grew 5.28% a year over 2 years.

    Shares Outstanding48.35M
    Shares Change (YoY)+8.28%
    Shares Change (QoQ)+6.41%
    Share Count Growth (2Y CAGR)+5.28%

    Valuation Ratios

    Sales and book value multiples are 1.0x and 2.0x. Its year-end P/S ranged from 1.1x to 3.8x from 2021 to 2025.

    P/S Ratio1.0x
    Forward P/S0.8x
    P/B Ratio2.0x

    Valuation history and multiples

    Price Statistics

    The stock is down 82.50% over 52 weeks and trades 17.78% below its 50-day average.

    Beta (1Y)1.79
    52-Week Change-82.50%
    1-Month Change-4.76%
    3-Month Change-56.66%
    6-Month Change-62.79%
    5-Year Change-96.39%
    Total Return (1Y)-82.50%
    Total Return (3Y CAGR)-10.27%
    Total Return (5Y CAGR)-46.16%
    Max Drawdown (1Y)-86.75%
    Max Drawdown (3Y)-86.75%
    Sharpe Ratio (1Y)-2.23
    Correlation with SPY (1Y)0.31
    50-Day Average$0.90
    200-Day Average$2.02
    52-Week Range$0.58 to $4.94
    RSI (14 Days)44.6
    Average Volume (20 Days)1.15M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.55x current liabilities, and total debt is 1.08x shareholder equity.

    Current Ratio2.55x
    Quick Ratio1.51x
    Debt / Equity1.08x
    Interest Coverage-21.20x

    Returns and Efficiency

    Return on invested capital is -135.11% over the last 12 months, against a 5-year average of -91.16%.

    Return on Equity (ROE)-288.48%
    Return on Assets (ROA)-87.60%
    Return on Invested Capital (ROIC)-135.11%
    Return on Capital Employed (ROCE)-123.67%
    ROE (5Y Average)-63.78%
    ROA (5Y Average)-41.93%
    ROIC (5Y Average)-91.16%
    Asset Turnover0.52x
    Inventory Turnover1.83x
    Receivables Turnover5.92x
    Cash Conversion Cycle207 days

    Scores

    RPID has an Altman Z-Score of -14.27, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-14.27
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $35.18M over the last 12 months is up 16.13% from the 12 months before.

    Revenue$35.18M
    Revenue Growth (YoY)+16.13%
    Gross Profit$1.95M
    Operating Income-$49.76M
    Pretax Income-$51.13M
    Net Income-$51.20M
    EBITDA-$46.69M
    EBIT-$49.84M
    Reported EPS (TTM)-$1.08

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 30.37% of the $58.45M in total assets.

    Cash and Equivalents$14.69M
    Total Debt$19.14M
    Net Debt$4.45M
    Net Debt Per Share$0.09
    Working Capital$28.11M
    Shareholder Equity$17.75M
    Book Value Per Share$0.37
    Total Assets$58.45M
    Total Liabilities$40.70M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $782.00K of capital spending, operating cash flow left -$40.84M of free cash flow.

    Operating Cash Flow-$40.06M
    Capital Expenditures$782.00K
    Free Cash Flow-$40.84M
    FCF Per Share-$0.89
    Depreciation and Amortization$3.15M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -141.45%.

    Gross Margin5.55%
    Operating Margin-141.45%
    Pretax Margin-145.34%
    Net Margin-145.55%
    EBITDA Margin-132.74%
    EBIT Margin-141.68%
    FCF Margin-116.10%
    Gross Margin (5Y Average)-20.96%

    Growth

    Revenue grew 25.15% a year over 3 years.

    Revenue Growth (3Y CAGR)+25.15%
    Revenue Growth (5Y CAGR)+15.88%
    Book Value Per Share Growth (2Y CAGR)-47.84%
    Tangible Book Per Share Growth (2Y CAGR)-47.84%

    Revenue and profit by year

    Dividends and Yields

    RPID does not pay a dividend. Its free cash flow yield is -114.65%.

    FCF Yield-114.65%
    Buyback Yield-28.92%
    Shareholder Yield-28.92%

    Peer Position

    Against 10 similar companies, RPID has the 8th highest P/S.

    P/S Ratio1.0x vs 2.6x median
    ROIC-135.11% vs -103.26% median
    Revenue Growth (Trailing 4 Quarters, YoY)+16.13% vs +6.36% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 16.58% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+16.58%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RPID

    What is RPID's market cap?

    Rapid Micro Biosystems has a market cap of $32.65M. Its enterprise value, which adds debt and subtracts cash, is $37.11M.

    How many shares of RPID are outstanding?

    Rapid Micro Biosystems has 48.35M shares outstanding. The count is up 8.28% from a year earlier.

    Does RPID pay a dividend?

    No. Rapid Micro Biosystems does not pay a dividend.

    How much debt does RPID have?

    Rapid Micro Biosystems has $19.14M of total debt and $14.69M of cash and equivalents, a net debt position of $4.45M.